KQ 2002
Alternative Names: KQ-2002Latest Information Update: 12 Jun 2024
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma; Lymphoid leukaemia
Most Recent Events
- 31 May 2024 Phase-I clinical trials in B-cell lymphoma (Recurrent, Second-line therapy or greater) in China (Parenteral) (NCT06445803)
- 31 May 2024 Phase-I clinical trials in Lymphoid leukaemia (Recurrent, Second-line therapy or greater) in China (Parenteral) (NCT06445803)
- 05 Apr 2024 Preclinical trials in B-cell lymphoma in China (Parenteral) (Novatim Immune Therapeutics pipeline, April 2024)